New Hope for Triple-Negative Breast Cancer: PUF60 Target Discovered! (2026)

A New Discovery in the Fight Against Aggressive Breast Cancer

In a groundbreaking revelation, researchers from the University of California San Diego have uncovered an important treatment target for triple-negative breast cancer (TNBC), which is recognized as the most aggressive form of breast cancer. This exciting study reveals that a protein known as PUF60 is crucial for the growth and survival of TNBC cells, as it regulates the splicing of essential genes. The findings indicate that when PUF60's function was disrupted in TNBC models, it led to significant errors in gene processing, resulting in DNA damage, halting the cell cycle, and ultimately leading to the death of tumor cells. Remarkably, this disruption did not seem to affect healthy cells.

Triple-negative breast cancer poses a major challenge in oncology due to its highly aggressive nature and its resistance to conventional targeted therapies, including immunotherapy and hormone treatments that are effective for other breast cancer subtypes. The absence of effective targeted therapies often results in a grim prognosis for patients diagnosed with TNBC. To combat this urgent issue, cancer researchers are diligently seeking innovative approaches to target this elusive type of cancer by attacking the cellular mechanisms that cancer cells exploit for their survival.

Among the critical discoveries highlighted in this new research are:

The team screened over 1,000 RNA-binding proteins present in TNBC cells and successfully identified 50 proteins that are vital for TNBC survival, with PUF60 standing out as a primary candidate.
When PUF60 was knocked down or when a specific mutation was introduced to hinder its function, researchers observed considerable DNA processing errors and a marked increase in cell death within TNBC models.
In various mouse models representing TNBC, the absence of PUF60 resulted in significant tumor shrinkage.
Importantly, the loss of PUF60 had minimal impact on healthy breast cells, indicating a potential therapeutic window.

This pivotal study sheds light on the role of PUF60-mediated RNA splicing as a promising avenue for developing new therapies for TNBC and potentially other cancers that experience replication stress. By identifying PUF60 as a key regulator that cancer cells rely on while healthy cells do not, these findings pave the way for future drug development efforts. Nonetheless, additional research is necessary to determine whether inhibitors targeting PUF60 or its splice-site interactions can be effectively developed as targeted cancer therapies.